# A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

> **NCT04533490** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 42 (estimated)

## Conditions studied

- Resectable Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** SHR-1210

## Key facts

- **NCT ID:** NCT04533490
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2021-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04533490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04533490, "A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04533490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*